{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-24-000112","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.108747+00:00","generated_at":"2026-06-01T03:17:37.648818+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Emergent BioSolutions sells Baltimore-Camden facility to Bora for $30M","bullets":["Sale of drug product facility to Bora Pharmaceuticals affiliate for total value of ~$30 million.","Approximately 350 Emergent employees expected to join Bora as part of the transaction.","Deal is part of multi-year plan to reduce debt, improve profitability, and streamline manufacturing to Lansing and Winnipeg.","Closing expected in Q3 2024, subject to customary conditions; Truist Securities and Covington & Burling advised Emergent."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-24-000112","json":"https://secwatch.observer/filing/0001367644-24-000112.json","markdown":"https://secwatch.observer/filing/0001367644-24-000112.md","text":"https://secwatch.observer/filing/0001367644-24-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000112/0001367644-24-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000112/ebs-20240620.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:17:37.648818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}